RT Journal Article
SR Electronic
T1 Long-term Outcome in Patients with Recurrent Malignant Glioma Treated with Perillyl Alcohol Inhalation
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5625
OP 5631
VO 33
IS 12
A1 DA FONSECA, CLOVIS O.
A1 TEIXEIRA, RAPHAEL M.
A1 SILVA, JÚLIO CESAR T.
A1 DE SALDANHA DA GAMA FISCHER, JULIANA
A1 MEIRELLES, OSÓRIO C.
A1 LANDEIRO, JOSE ALBERTO
A1 QUIRICO-SANTOS, THEREZA
YR 2013
UL http://ar.iiarjournals.org/content/33/12/5625.abstract
AB Aim: This retrospective study aimed to evaluate the long-term response and toxicity of recurrent malignant glioma patients to inhalation chemotherapy with perillyl alcohol (POH). Patients and Methods: The cohort included 117 men and 81 women with primary glioblastoma multiforme (GBM; n=154), grade III astrocytoma (AA; n=26) and anaplastic oligodendroglioma (AO; n=5). POH inhalation schedule 4-times daily started with 66.7 mg/dose; 266 mg/day and escalated up to 133.4 mg/dose; 533.6 mg/day. Clinical toxicity and overall survival following treatment were compared with tumor size, topography, extent of peritumoral edema and histological classification. Results: Adhesion to the protocol was high (>95%), POH (533.6 mg/daily) occasionally caused nose soreness but rarely nosebleed. Tumor size, peritumoral edema and the oligodendroglial component influenced response to treatment. Conclusion: After 4 years under exclusive POH treatment, 19% of patients still remain in clinical remission. Long-term POH inhalation chemotherapy is a safe and non-invasive strategy efficient for recurrent malignant glioma.